• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

适应性富集设计中的盲法样本量重估。

Blinded sample size recalculation in adaptive enrichment designs.

机构信息

Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.

DZHK (German Center for Cardiovascular Research), partner site Göttingen, Göttingen, Germany.

出版信息

Biom J. 2023 Feb;65(2):e2000345. doi: 10.1002/bimj.202000345. Epub 2022 Aug 19.

DOI:10.1002/bimj.202000345
PMID:35983952
Abstract

In the precision medicine era, (prespecified) subgroup analyses are an integral part of clinical trials. Incorporating multiple populations and hypotheses in the design and analysis plan, adaptive designs promise flexibility and efficiency in such trials. Adaptations include (unblinded) interim analyses (IAs) or blinded sample size reviews. An IA offers the possibility to select promising subgroups and reallocate sample size in further stages. Trials with these features are known as adaptive enrichment designs. Such complex designs comprise many nuisance parameters, such as prevalences of the subgroups and variances of the outcomes in the subgroups. Additionally, a number of design options including the timepoint of the sample size review and timepoint of the IA have to be selected. Here, for normally distributed endpoints, we propose a strategy combining blinded sample size recalculation and adaptive enrichment at an IA, that is, at an early timepoint nuisance parameters are reestimated and the sample size is adjusted while subgroup selection and enrichment is performed later. We discuss implications of different scenarios concerning the variances as well as the timepoints of blinded review and IA and investigate the design characteristics in simulations. The proposed method maintains the desired power if planning assumptions were inaccurate and reduces the sample size and variability of the final sample size when an enrichment is performed. Having two separate timepoints for blinded sample size review and IA improves the timing of the latter and increases the probability to correctly enrich a subgroup.

摘要

在精准医学时代,(预设)亚组分析是临床试验的一个组成部分。在设计和分析计划中纳入多个群体和假设,适应性设计承诺在这些试验中具有灵活性和效率。适应性设计包括(非盲)中期分析(IA)或盲样本量审查。IA 提供了选择有前途的亚组并在进一步阶段重新分配样本量的可能性。具有这些特征的试验被称为适应性富集设计。这种复杂的设计包括许多干扰参数,例如亚组的患病率和亚组中结果的方差。此外,还必须选择许多设计选项,包括样本量审查的时间点和 IA 的时间点。在这里,对于正态分布的终点,我们提出了一种结合盲法样本量重算和 IA 适应性富集的策略,即在早期,重新估计干扰参数,并调整样本量,同时进行亚组选择和富集。我们讨论了不同方差情景以及盲法审查和 IA 时间点的影响,并在模拟中研究了设计特征。如果规划假设不准确,该方法可保持所需的功效,并在进行富集时减少样本量和最终样本量的变异性。对于盲法样本量审查和 IA 有两个单独的时间点,可以改善后者的时间安排,并增加正确富集亚组的可能性。

相似文献

1
Blinded sample size recalculation in adaptive enrichment designs.适应性富集设计中的盲法样本量重估。
Biom J. 2023 Feb;65(2):e2000345. doi: 10.1002/bimj.202000345. Epub 2022 Aug 19.
2
Clinical trials with nested subgroups: Analysis, sample size determination and internal pilot studies.嵌套亚组的临床试验:分析、样本量确定和内部预试验研究。
Stat Methods Med Res. 2018 Nov;27(11):3286-3303. doi: 10.1177/0962280217696116. Epub 2017 Mar 14.
3
Timing of the interim analysis in adaptive enrichment designs.适应性富集设计中的期中分析时机。
J Biopharm Stat. 2018;28(4):622-632. doi: 10.1080/10543406.2017.1372769. Epub 2017 Oct 30.
4
Smoothing Corrections for Improving Sample Size Recalculation Rules in Adaptive Group Sequential Study Designs.平滑校正改进适应性分组序贯研究设计中的样本量重估规则。
Methods Inf Med. 2021 May;60(1-02):1-8. doi: 10.1055/s-0040-1721727. Epub 2021 Mar 1.
5
A new conditional performance score for the evaluation of adaptive group sequential designs with sample size recalculation.一种用于评估具有样本量重新计算的适应性成组序贯设计的新条件性能评分。
Stat Med. 2020 Jul 10;39(15):2067-2100. doi: 10.1002/sim.8534. Epub 2020 Apr 6.
6
Improving sample size recalculation in adaptive clinical trials by resampling.通过重采样改进自适应临床试验中的样本量重新计算。
Pharm Stat. 2021 Nov;20(6):1035-1050. doi: 10.1002/pst.2122. Epub 2021 Apr 1.
7
Blinded sample size recalculation in clinical trials with binary composite endpoints.具有二元复合终点的临床试验中的盲法样本量重新计算
J Biopharm Stat. 2017;27(4):705-715. doi: 10.1080/10543406.2016.1198371. Epub 2016 Jun 13.
8
Sample size recalculation in three-stage clinical trials and its evaluation.三阶段临床试验中的样本量重估及其评价。
BMC Med Res Methodol. 2024 Sep 25;24(1):214. doi: 10.1186/s12874-024-02337-9.
9
Sample size re-estimation in adaptive enrichment design.适应性富集设计中的样本量再估计。
Contemp Clin Trials. 2021 Jan;100:106216. doi: 10.1016/j.cct.2020.106216. Epub 2020 Nov 24.
10
Sample size recalculation based on the prevalence in a randomized test-treatment study.基于随机试验-治疗研究中患病率的样本量重新计算。
BMC Med Res Methodol. 2022 Jul 25;22(1):205. doi: 10.1186/s12874-022-01678-7.